Compare LPSN & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | TELA |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 36.7M |
| IPO Year | 2000 | 2019 |
| Metric | LPSN | TELA |
|---|---|---|
| Price | $3.00 | $0.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | ★ 92.8K | 63.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,838,000.00 | $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $0.39 | $0.67 |
| 52 Week High | $7.54 | $2.48 |
| Indicator | LPSN | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 52.61 |
| Support Level | $2.94 | $0.67 |
| Resistance Level | $4.23 | $0.93 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 46.32 | 81.18 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.